Cargando…

The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study

BACKGROUND: Trimethylamine N-oxide (TMAO), a metabolite from red meat and fish consumption, plays a role in promoting cardiovascular events. However, data regarding TMAO and its impact on clinical outcomes are inconclusive, possibly due to its undetermined dietary source. OBJECTIVES: We hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Lu, Massy, Ziad A, Stenvinkel, Peter, Chesnaye, Nicholas C, Larabi, Islam Amine, Alvarez, Jean Claude, Caskey, Fergus J, Torino, Claudia, Porto, Gaetana, Szymczak, Maciej, Krajewska, Magdalena, Drechsler, Christiane, Wanner, Christoph, Jager, Kitty J, Dekker, Friedo W, Evenepoel, Pieter, Evans, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761748/
https://www.ncbi.nlm.nih.gov/pubmed/36166845
http://dx.doi.org/10.1093/ajcn/nqac278
_version_ 1784852741663752192
author Dai, Lu
Massy, Ziad A
Stenvinkel, Peter
Chesnaye, Nicholas C
Larabi, Islam Amine
Alvarez, Jean Claude
Caskey, Fergus J
Torino, Claudia
Porto, Gaetana
Szymczak, Maciej
Krajewska, Magdalena
Drechsler, Christiane
Wanner, Christoph
Jager, Kitty J
Dekker, Friedo W
Evenepoel, Pieter
Evans, Marie
author_facet Dai, Lu
Massy, Ziad A
Stenvinkel, Peter
Chesnaye, Nicholas C
Larabi, Islam Amine
Alvarez, Jean Claude
Caskey, Fergus J
Torino, Claudia
Porto, Gaetana
Szymczak, Maciej
Krajewska, Magdalena
Drechsler, Christiane
Wanner, Christoph
Jager, Kitty J
Dekker, Friedo W
Evenepoel, Pieter
Evans, Marie
author_sort Dai, Lu
collection PubMed
description BACKGROUND: Trimethylamine N-oxide (TMAO), a metabolite from red meat and fish consumption, plays a role in promoting cardiovascular events. However, data regarding TMAO and its impact on clinical outcomes are inconclusive, possibly due to its undetermined dietary source. OBJECTIVES: We hypothesized that circulating TMAO derived from fish intake might cause less harm compared with red meat sources by examining the concomitant level of 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), a known biomarker of fish intake, and investigated the association between TMAO, CMPF, and outcomes. METHODS: Patients were recruited from the European QUALity (EQUAL) Study on treatment in advanced chronic kidney disease among individuals aged ≥65 y whose estimated glomerular filtration rate (eGFR) had dropped for the first time to ≤20 mL/min per 1.73 m(2) during the last 6 mo. The association between TMAO, CMPF, and outcomes including all-cause mortality and kidney replacement therapy (KRT) was assessed among 737 patients. Patients were further stratified by median cutoffs of TMAO and CMPF, suggesting high/low red meat and fish intake. RESULTS: During a median of 39 mo of follow-up, 232 patients died. Higher TMAO was independently associated with an increased risk of all-cause mortality (multivariable HR: 1.46; 95% CI: 1.17, 1.83). Higher CMPF was associated with a reduced risk of both all-cause mortality (HR: 0.79; 95% CI: 0.71, 0.89) and KRT (HR: 0.80; 95% CI: 0.71, 0.90), independently of TMAO and other clinically relevant confounders. In comparison to patients with low TMAO and CMPF, patients with low TMAO and high CMPF had reduced risk of all-cause mortality (adjusted HR: 0.49; 95% CI: 0.31, 0.73), whereas those with high TMAO and high CMPF showed no association across adjusted models. CONCLUSIONS: High CMPF conferred an independent role in health benefits and might even counteract the unfavorable association between TMAO and outcomes. Whether higher circulating CMPF concentrations are due to fish consumption, and/or if CMPF is a protective factor, remains to be verified.
format Online
Article
Text
id pubmed-9761748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97617482022-12-20 The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study Dai, Lu Massy, Ziad A Stenvinkel, Peter Chesnaye, Nicholas C Larabi, Islam Amine Alvarez, Jean Claude Caskey, Fergus J Torino, Claudia Porto, Gaetana Szymczak, Maciej Krajewska, Magdalena Drechsler, Christiane Wanner, Christoph Jager, Kitty J Dekker, Friedo W Evenepoel, Pieter Evans, Marie Am J Clin Nutr Original Research Communications BACKGROUND: Trimethylamine N-oxide (TMAO), a metabolite from red meat and fish consumption, plays a role in promoting cardiovascular events. However, data regarding TMAO and its impact on clinical outcomes are inconclusive, possibly due to its undetermined dietary source. OBJECTIVES: We hypothesized that circulating TMAO derived from fish intake might cause less harm compared with red meat sources by examining the concomitant level of 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), a known biomarker of fish intake, and investigated the association between TMAO, CMPF, and outcomes. METHODS: Patients were recruited from the European QUALity (EQUAL) Study on treatment in advanced chronic kidney disease among individuals aged ≥65 y whose estimated glomerular filtration rate (eGFR) had dropped for the first time to ≤20 mL/min per 1.73 m(2) during the last 6 mo. The association between TMAO, CMPF, and outcomes including all-cause mortality and kidney replacement therapy (KRT) was assessed among 737 patients. Patients were further stratified by median cutoffs of TMAO and CMPF, suggesting high/low red meat and fish intake. RESULTS: During a median of 39 mo of follow-up, 232 patients died. Higher TMAO was independently associated with an increased risk of all-cause mortality (multivariable HR: 1.46; 95% CI: 1.17, 1.83). Higher CMPF was associated with a reduced risk of both all-cause mortality (HR: 0.79; 95% CI: 0.71, 0.89) and KRT (HR: 0.80; 95% CI: 0.71, 0.90), independently of TMAO and other clinically relevant confounders. In comparison to patients with low TMAO and CMPF, patients with low TMAO and high CMPF had reduced risk of all-cause mortality (adjusted HR: 0.49; 95% CI: 0.31, 0.73), whereas those with high TMAO and high CMPF showed no association across adjusted models. CONCLUSIONS: High CMPF conferred an independent role in health benefits and might even counteract the unfavorable association between TMAO and outcomes. Whether higher circulating CMPF concentrations are due to fish consumption, and/or if CMPF is a protective factor, remains to be verified. Oxford University Press 2022-09-27 /pmc/articles/PMC9761748/ /pubmed/36166845 http://dx.doi.org/10.1093/ajcn/nqac278 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Communications
Dai, Lu
Massy, Ziad A
Stenvinkel, Peter
Chesnaye, Nicholas C
Larabi, Islam Amine
Alvarez, Jean Claude
Caskey, Fergus J
Torino, Claudia
Porto, Gaetana
Szymczak, Maciej
Krajewska, Magdalena
Drechsler, Christiane
Wanner, Christoph
Jager, Kitty J
Dekker, Friedo W
Evenepoel, Pieter
Evans, Marie
The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study
title The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study
title_full The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study
title_fullStr The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study
title_full_unstemmed The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study
title_short The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study
title_sort association between tmao, cmpf, and clinical outcomes in advanced chronic kidney disease: results from the european quality (equal) study
topic Original Research Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761748/
https://www.ncbi.nlm.nih.gov/pubmed/36166845
http://dx.doi.org/10.1093/ajcn/nqac278
work_keys_str_mv AT dailu theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT massyziada theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT stenvinkelpeter theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT chesnayenicholasc theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT larabiislamamine theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT alvarezjeanclaude theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT caskeyfergusj theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT torinoclaudia theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT portogaetana theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT szymczakmaciej theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT krajewskamagdalena theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT drechslerchristiane theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT wannerchristoph theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT jagerkittyj theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT dekkerfriedow theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT evenepoelpieter theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT evansmarie theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT theassociationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT dailu associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT massyziada associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT stenvinkelpeter associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT chesnayenicholasc associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT larabiislamamine associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT alvarezjeanclaude associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT caskeyfergusj associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT torinoclaudia associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT portogaetana associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT szymczakmaciej associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT krajewskamagdalena associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT drechslerchristiane associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT wannerchristoph associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT jagerkittyj associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT dekkerfriedow associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT evenepoelpieter associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT evansmarie associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy
AT associationbetweentmaocmpfandclinicaloutcomesinadvancedchronickidneydiseaseresultsfromtheeuropeanqualityequalstudy